Last updated on February 2020

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation

Brief description of study

This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.

Detailed Study Description

PLB1001 will be administrated 200mg twice daily. The treatment will be discontinued for the patients who experience disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent. A cycle of study treatment will be defined as 28 days of continuous dosing. The study includes 4 cohorts.

Clinical Study Identifier: NCT04258033

Find a site near you

Start Over

Guangdong General Hospital

Guangzhou, China
  Connect »